Zosuquidar trihydrochloride 3HCL, also known as LY335979, is a potent and selective inhibitor of P-glycoprotein (P-gp), a protein that plays a critical role in drug resistance in cancer cells. This article will provide an overview of zosuquidar trihydrochloride 3HCL, including its chemical name, molecular formula, CAS number, health benefits, potential effects, product mechanism, safety, side effects, dosing information, and conclusion.
Introduce this product: Zosuquidar trihydrochloride 3HCL is a novel drug that has been developed to overcome the problem of multidrug resistance in cancer cells. It is an ATP-binding cassette transporter inhibitor that selectively inhibits P-gp, which is overexpressed in many types of cancers, including breast, ovarian, lung, and colon cancer. By blocking the activity of P-gp, zosuquidar trihydrochloride 3HCL can increase the effectiveness of chemotherapy drugs and reduce the risk of treatment failure.
Chemical name: Zosuquidar trihydrochloride 3HCL
Molecular formula: C32H35N6O2.3HCl
Formula weight: 665.05 g/mol
CAS No: 167465-36-3
Top ten keywords from Google and Synonyms:
Health benefits of this product: Zosuquidar trihydrochloride 3HCL has been shown to improve the efficacy of chemotherapy drugs in cancer patients by overcoming multidrug resistance. It is particularly effective in breast cancer and ovarian cancer, both of which are known to be resistant to chemotherapy. In addition, zosuquidar trihydrochloride 3HCL has been shown to have a synergistic effect when used in combination with other chemotherapeutic agents, such as doxorubicin and paclitaxel.
Potential effects: The potential effects of zosuquidar trihydrochloride 3HCL include increased sensitivity of cancer cells to chemotherapy drugs, improved therapeutic outcomes, and reduced risk of treatment failure. It can also help reduce the need for high-dose chemotherapy, which can have severe side effects. Additionally, zosuquidar trihydrochloride 3HCL may have applications beyond cancer treatment, such as in the treatment of HIV infections and parasitic diseases.
Product mechanism: Zosuquidar trihydrochloride 3HCL works by selectively inhibiting P-gp, a membrane-bound protein that pumps drugs out of cancer cells, reducing their effectiveness. By blocking the activity of P-gp, zosuquidar trihydrochloride 3HCL allows chemotherapy drugs to accumulate in cancer cells, increasing their toxicity and ultimately leading to cancer cell death.
Safety: Zosuquidar trihydrochloride 3HCL has been shown to be safe and well-tolerated in clinical trials. However, like all drugs, it can cause side effects in some patients. It is important to discuss potential risks and benefits with your doctor before starting any new medication.
Side effects: The most common side effects of zosuquidar trihydrochloride 3HCL include nausea, vomiting, diarrhea, fatigue, and headache. Less common side effects include hair loss, skin rash, and changes in blood pressure. In rare cases, zosuquidar trihydrochloride 3HCL can cause serious allergic reactions or liver damage.
Dosing information: The optimal dose of zosuquidar trihydrochloride 3HCL varies depending on the type and stage of cancer being treated, as well as other factors such as age and overall health. It is important to follow your doctor's instructions carefully and not adjust your dosage without consulting them first.
Conclusion: Zosuquidar trihydrochloride 3HCL is a promising new drug that has the potential to improve the efficacy of chemotherapy in cancer patients by overcoming multidrug resistance. It works by selectively inhibiting P-gp, a protein that pumps drugs out of cancer cells, allowing chemotherapy drugs to accumulate and increase their toxicity. While zosuquidar trihydrochloride 3HCL is generally safe and well-tolerated, it can cause side effects in some patients. It is important to discuss potential risks and benefits with your doctor before starting any new medication